What is the 13F Pro Quality Score for PBH?

13F Pro ranks Prestige Consumer Healthcare Inc. (PBH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PBH's current score at https://13fpro.ai/research/PBH (free sign-up required for the full ranking).

Which hedge funds own the most PBH stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PBH include BlackRock,, ARIEL INVESTMENTS,, VANGUARD PORTFOLIO MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PBH as soon as new 13F filings post.

Where does 13F Pro source PBH data?

All Prestige Consumer Healthcare Inc. fundamentals and ownership data come directly from SEC EDGAR. Prestige Consumer Healthcare Inc. files with the SEC under CIK 1295947. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PBH in?

Prestige Consumer Healthcare Inc. (PBH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PBH research updated on 13F Pro?

PBH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Prestige Consumer Healthcare Inc.(PBH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1295947 PBH stock profile & AI dashboard →

13F Pro Quality Score

61.2/100

Rank #816 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

29.2/100

Profitability

80.1/100

Balance Sheet

73.2/100

Earnings Quality

34.0/100

Free Cash Flow

82.2/100

Institutional Flow

75.0/100

Revenue Scale

51.1/100

Dilution Risk

57.2/100

PBH Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Prestige Consumer Healthcare Inc. (PBH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PBH at 61.2/100 on a 32-signal composite quality model, placing it at rank #816 of 2,879 stocks — the top half of the AI-ranked universe. PBH scores in the top quartile across free cash flow (82.2), profitability (80.1), institutional flow (75.0). Areas of concern include revenue growth (29.2) and earnings quality (34.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q4 2026), Prestige Consumer Healthcare Inc. reports quarterly revenue of $281.6M, net income of $53.9M, an operating margin of 26.8%. Top institutional holders of PBH by reported 13-F value include BlackRock,, ARIEL INVESTMENTS,, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. PBH trades on the NYSE exchange and files with the SEC under CIK 1295947. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PBH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Prestige Consumer Healthcare Inc. directly from SEC EDGAR. Prestige Consumer Healthcare Inc.'s 13F Pro composite quality score has ranged between 57 and 67 since 2021, currently 61.2 — a declining long-term trajectory across 30 quarterly and live scoring snapshots.

Revenue

Q4 2026

$281.6M

Net Income

Q4 2026

$53.9M

Free Cash Flow

Q4 2026

$37.6M

Operating Margin

Q4 2026

26.8%

ROIC

Q4 2026

2.6%

D/E Ratio

Q4 2026

0.53

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-4.3% YoY

$1.09BFY 2026

FY23 $1.13BFY24 $1.13BFY25 $1.14BFY26 $1.09B

Net Income

-11.3% YoY

$190.3MFY 2026

FY23 $-82.3MFY24 $209.3MFY25 $214.6MFY26 $190.3M

Operating Income

-8.1% YoY

$309.4MFY 2026

FY23 $-22.4MFY24 $342.4MFY25 $336.8MFY26 $309.4M

EPS (Diluted)

-8.9% YoY

$3.91FY 2026

FY23 $-1.65FY24 $4.17FY25 $4.29FY26 $3.91

Total Assets

+2.7% YoY

$3.49BFY 2026

FY23 $3.35BFY24 $3.32BFY25 $3.40BFY26 $3.49B

Total Debt

+0.2% YoY

$994.0MFY 2026

FY23 $1.36BFY24 $1.14BFY25 $992.4MFY26 $994.0M

Op. Cash Flow

+2.4% YoY

$257.6MFY 2026

FY23 $229.7MFY24 $248.9MFY25 $251.5MFY26 $257.6M

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$1.09B -4.3%	$1.14B +1.1%	$1.13B -0.2%	$1.13B +3.8%	$1.09B +15.2%	$943.4M
Net Income	$190.3M -11.3%	$214.6M +2.5%	$209.3M +354.3%	$-82.3M -140.1%	$205.4M +24.7%	$164.7M
Operating Income	$309.4M -8.1%	$336.8M -1.7%	$342.4M +1627.7%	$-22.4M -106.8%	$329.9M +10.9%	$297.4M
EPS (Diluted)	$3.91 -8.9%	$4.29 +2.9%	$4.17 +352.7%	$-1.65 -140.8%	$4.04 +24.3%	$3.25
Total Assets	$3.49B +2.7%	$3.40B +2.5%	$3.32B -1.1%	$3.35B -8.6%	$3.67B +7.0%	$3.43B
Total Debt	$994.0M +0.2%	$992.4M -12.6%	$1.14B -16.5%	$1.36B -7.9%	$1.48B -1.2%	$1.50B
Operating Cash Flow	$257.6M +2.4%	$251.5M +1.0%	$248.9M +8.4%	$229.7M -11.6%	$259.9M +10.3%	$235.6M

AI Insight: PBH Financial Trends

Revenue growth stalled while operating margins compressed; debt stable but equity expansion masks underlying operational softness.

• Revenue declined 5% from Q4 2024 peak ($290M) to Q1 2026 ($282M), with Q2 2025 dipping to $250M.

• Operating margin compressed from 31.7% in Q4 2024 to 26.6% in Q1 2026, a 510 bp contraction.

• Operating cash flow halved from $78M in Q4 2025 to $43M in Q1 2026, signaling working capital or collection headwinds.

• Total debt stable at ~$993–$1,034M over past four quarters; leverage remains flat.

⚠ Net income volatility persists ($42M–$61M range); Q1 2026 recovery to $54M insufficient to offset margin erosion.

⚠ Operating cash flow deterioration in Q1 2026 ($43M) despite stable OpInc suggests cash conversion or timing risk.

AI Insight: PBH Ratio Trends

Prestige's profitability inflected downward in 2025; operating margin and ROIC both peaked in Q4 2024 and have not recovered.

• Operating margin peaked at 31.7% in Q4 2024, declined to 26.8% in Q1 2026—a 90 basis point deterioration from TTM.

• ROIC fell from 13.2% in Q4 2024 to 10.5% in Q1 2026, a three-year low despite stable leverage near 0.53–0.56.

• Net profit margin volatile: 21.0% in Q4 2024, compressed to 15.4% in Q3 2025, recovered to 19.1% in Q1 2026.

⚠ ROE and ROA both tracking near their lowest levels in the dataset (10.2% and 5.3% respectively) despite leverage stable.

⚠ Net profit margin remains below Q4 2024 peak; whether Q1 2026's 19.1% recovery signals stabilization or temporary bounce unclear.

Get alerted when PBH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Prestige Consumer Healthcare Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PBH

BlackRock, Inc.
$437.9M7,388,490 sh
ARIEL INVESTMENTS, LLC
$253.3M4,274,326 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$166.2M2,803,828 sh
DIMENSIONAL FUND ADVISORS LP
$158.4M2,672,777 sh
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC
$130.5M2,202,606 sh
VANGUARD CAPITAL MANAGEMENT LLC
$124.1M2,092,993 sh
STATE STREET CORP
$116.8M1,970,981 sh
Allspring Global Investments Holdings, LLC
$89.9M1,558,104 sh
GEODE CAPITAL MANAGEMENT, LLC
$86.5M1,460,035 sh
MORGAN STANLEY
$80.5M1,357,470 sh

Fund	Value	Shares
BlackRock, Inc.	$437.9M	7,388,490
ARIEL INVESTMENTS, LLC	$253.3M	4,274,326
VANGUARD PORTFOLIO MANAGEMENT LLC	$166.2M	2,803,828
DIMENSIONAL FUND ADVISORS LP	$158.4M	2,672,777
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC	$130.5M	2,202,606
VANGUARD CAPITAL MANAGEMENT LLC	$124.1M	2,092,993
STATE STREET CORP	$116.8M	1,970,981
Allspring Global Investments Holdings, LLC	$89.9M	1,558,104
GEODE CAPITAL MANAGEMENT, LLC	$86.5M	1,460,035
MORGAN STANLEY	$80.5M	1,357,470

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PBH on your watchlist

Track score changes the day Prestige Consumer Healthcare Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PBH a good stock to buy?

13F Pro's AI-powered analysis of Prestige Consumer Healthcare Inc. (PBH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PBH are available on the PBH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PBH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PBH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Prestige Consumer Healthcare Inc.'s investment landscape.